Avastin® (bevacizumab) is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF. Normal cells make VEGF, but some cancer cells make too much VEGF. Blocking VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors.
Unlike chemotherapy that attacks the cancer cells, the purpose of Avastin is to block the blood supply that feeds the tumor. This can stop the tumor from growing.
New blood vessels feed the tumor so it can grow and spread.
Avastin helps prevent blood vessels from reaching the tumor; this could starve the tumor.
However, in a study of mCRC patients who continued on Avastin for second-line treatment after a first-line treatment containing bevacizumab, tumors did not shrink.
Questions about Avastin treatment costs? Let us help you understand your financial assistance options.
Avastin is a tumor-starving therapy. Read more about how it's designed to work.
Find helpful information and support.
The information contained in this section of the site is intended for U.S. healthcare professionals only. Click "OK" if you are a healthcare professional.
The link you have selected will take you away from this site to one that is not owned or controlled by Genentech, Inc. Genentech, Inc. makes no representation as to the accuracy of the information contained on sites we do not own or control. Genentech does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.